CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 60 target
Drug / intervention
IRSW-MIMdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06478108
NCT06478108Phase 3RecruitingOn TrackUpdated 24mo ago
CompareCT.gov

Interventional Software IRSW-MIM Guided Immunotherapy for Advanced Solid Tumors: a Phase II Clinical Trial.

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jun 27, 2024·Updated Jun 27, 2024

In Brief

A Phase 3 clinical trial evaluating IRSW-MIM for Lung Cancer and 2 related conditions. Currently recruiting, targeting 60 participants across 1 site.

Detailed Summary

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by intra-tumor (IT) injection of multiple drugs including CTLA4, PD1, and/or PDL1 antibodies combined with drugs-eluting beads loaded with IL2, chemodrug, anti-angiogenesis drug, et. al that will be recommended by an AI-based medical software named IRSW-MIM developed by a cooperating company.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Liver Cancer, Solid Tumor, Adult
CountriesChina
CollaboratorsImmuno (Guangzhou) Biomedicine S&T Ltd

Timeline

Phase 3Recruiting
20242025202620272028202920302031203220332034
First PostedJun 27, 2024
Enrollment StartApr 1, 2024
Primary CompletionDec 30, 2028
Study CompletionDec 30, 2033
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 2.0 years agoPrimary completion in 2.5 years

Interventions

IRSW-MIMdevice

IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.